Kymab Ltd | Home
             
Pause Play
Kymab expands into dedicated labs to support work in target disease areas.
Kymab is attending key partnering events in 2014, if you wish to talk email us at partnering@kymab.com
Kymab announces Kymouse Antibody Discovery Agreement with Novo Nordisk.
Kymab appoints Dr Christian Groendahl as Chief Executive Officer and Dr David Chiswell as Chairman.
Kymab starts academic collaboration program to facilitate translational research.
Kymab expands into dedicated labs to support work in target disease areas.
Kymab is attending key partnering events in 2014, if you wish to talk email us at partnering@kymab.com
Kymab announces Kymouse Antibody Discovery Agreement with Novo Nordisk.
Kymab appoints Dr Christian Groendahl as Chief Executive Officer and Dr David Chiswell as Chairman.
Kymab starts academic collaboration program to facilitate translational research.
Kymab expands into dedicated labs to support work in target disease areas.
Kymab is attending key partnering events in 2014, if you wish to talk email us at partnering@kymab.com
Kymab announces Kymouse Antibody Discovery Agreement with Novo Nordisk.
Kymab appoints Dr Christian Groendahl as Chief Executive Officer and Dr David Chiswell as Chairman.
Kymab starts academic collaboration program to facilitate translational research.

Advanced therapeutic antibody discovery & development

Kymab is discovering and developing fully human monoclonal antibody therapeutics using our pioneering transgenic mouse platform. We are building a rich pipeline in 5 therapeutic areas: haematology, oncology, auto-immunity, pain and cardiovascular disease.

Perfecting discovery

Kymouse™ is transforming the discovery of very high affinity fully human monoclonal antibodies against a broad range of drug targets and has been designed to overcome the limitations of previous humanised transgenic antibody platforms.

Partnering

Kymab discovers and develops its drugs both independently and in collaboration with pharmaceutical, biotechnology and academic partners. We are employing our proprietary technologies, including Kymouse™ to discover, develop and commercialise monoclonal antibody medicines to difficult and novel drug targets.